Figure 1. Study population diagram

Slides:

Advertisements

Similar presentations

Figure 1 Overall design of Query Health

Advertisements

Fig. 4. Carer ratings of executive functioning (Dysexecutive Questionnaire) and memory (Memory Checklist) in the 3 groups at the beginning and end of the.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.

From: Dynamic De/Centralization in Canada, 1867–2010

Figure 3: (a and b) Preoperative contrast-eCT

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

J Exp Bot. 2017;68(17): doi: /jxb/erx352

Figure 2. Chronic kidney disease risk tool application.

Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.

Fig 1 The CONSORT participant flow diagram for primary endpoints.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

From: THE FALLACIES OF PATENT-HOLDUP THEORY

Fig. 1. Trial structure for the experimental task.

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Nutrition and brain development in early life

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Detection of Bacteriuria by Canine Olfaction

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 2. Temperature-entropy diagram and the flow resistances of the power plant model of Figure 1. From: Thermodynamic optimization of a triple-shaft.

Fig. 1 No. 17 Trinidad trap baited with hamster in swamp forest in Tennessee. (Online figure in color.) From: Use of Hamster-Baited No. 17 Trinidad Mosquito.

Fig. 1. RUbioSeq pipelines for exome variant detection and BS-Seq analyses. Dark gray boxes correspond to the main steps of the pipelines. Light gray boxes.

Figure 3: Full-body skeletal scintigraphy.

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

From: Herpes Zoster and Recurrent Herpes Zoster

Figure 1. Percentage of infants with enzyme-linked immunosorbent assay antibody concentrations ≥0.1 IU/mL against diphtheria (day 127) and ≥0.35 μg/mL.

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Figure 2 Mean pain intensity and pain relief over 12 hours of treatment (ITT population). *Difference from baseline (P

Figure 3. Scatterplot of hue and colour saturation (chroma) for the five Aphelocoma unicolor subspecies. From: Cloudy with a chance of speciation: integrative.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

ADAb: anti-drug antibody.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 4. Levels of cerebrospinal fluid (CSF) immune and inflammatory markers in participants grouped by CSF human ... Figure 4. Levels of cerebrospinal.

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Excess cost of methicillin-resistant Staphylococcus aureus (MRSA) compared with methicillin-susceptible S. ... Figure 1. Excess cost of methicillin-resistant.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Figure 3. Multiply-budding yeast-like cells of Blastomyces helicus in calcofluor white stain of bronchoalveolar fluid ... Figure 3. Multiply-budding yeast-like.

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Figure 1. The C-Mill and the 7 C-Gait walking-adaptability tasks.

Presentation transcript:

Figure 1. Study population diagram Figure 1. Study population diagram. Abbreviations: ART, antiretroviral therapy; TB, tuberculosis. From: Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria Open Forum Infect Dis. 2015;2(4). doi:10.1093/ofid/ofv154 Open Forum Infect Dis | © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Figure 2. Rate of first incident tuberculosis (TB) occurrence by duration on antiretroviral therapy (ART). Abbreviations: CI, confidence interval; PY, person-years. From: Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria Open Forum Infect Dis. 2015;2(4). doi:10.1093/ofid/ofv154 Open Forum Infect Dis | © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Figure 3. Kaplan-Meier tuberculosis (TB)-free survival curve with 95% confidence interval (CI). Abbreviation: ART, antiretroviral therapy. From: Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria Open Forum Infect Dis. 2015;2(4). doi:10.1093/ofid/ofv154 Open Forum Infect Dis | © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Figure 4. Tuberculosis (TB) rates by the President's Emergency Plan for AIDS Relief (PEPFAR) program year: percentage prevalent TB of patients initiating antiretroviral therapy (ART) 2005–2010 (A) and rate of first incidence TB occurrence during ART 2006–2011 (B). Abbreviations: CI, 95% confidence interval; pts, patients. From: Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria Open Forum Infect Dis. 2015;2(4). doi:10.1093/ofid/ofv154 Open Forum Infect Dis | © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.